background preloader

Vacunas

Facebook Twitter

CDC 03.03 Interim Clinical Considerations for Use of COVID-19 Vaccines. Summary of recent changes (last updated March 3, 2021): Clinical considerations added for use of Janssen (Johnson & Johnson) COVID-19 vaccine.Updated recommendations for fully vaccinated people who subsequently develop COVID-19.Updated recommendations related to COVID-19 vaccination timing for immunocompromised people.Updated contraindications and precautions to mRNA COVID-19 vaccines.Updated information on interpretation of SARS-CoV-2 antibody test results after vaccination.

CDC 03.03 Interim Clinical Considerations for Use of COVID-19 Vaccines

Key points The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of Pfizer-BioNTech, Moderna, and Janssen (Johnson & Johnson) COVID-19 vaccines for the prevention of coronavirus disease 2019 (COVID-19) in the United States. 04.03 Variantes Covid. Jama moore 04.03 2021 Vacunas y variantes. MPR 02.03 COVID 19 Vaccine Efficacy After First Dose Pfizer, Moderna, AstraZeneca. Nejm03,03,21 Preferencias individuales con las vacunas. Coronavirus (COVID-19) Update: Vaccines and Immunity. MMWR 02.03.21 The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine. Sara E.

MMWR 02.03.21 The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine

Oliver, MD1; Julia W. Gargano, PhD1; Heather Scobie, PhD1; Megan Wallace, DrPH1,2; Stephen C. Hadler, MD1; Jessica Leung, MPH1; Amy E. Blain, MPH1; Nancy McClung, PhD1; Doug Campos-Outcalt, MD3; Rebecca L. Morgan, PhD4; Sarah Mbaeyi, MD1; Jessica MacNeil, MPH1; José R. View suggested citation Summary What is already known about this topic? On February 27, 2021, the Food and Drug Administration issued an Emergency Use Authorization (EUA) for the Janssen COVID-19 vaccine. What is added by this report? On February 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Janssen COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19.

What are the implications for public health practice? Vacunas covid pacientes MERIDA. Early effectiveness of COVID vaccines con 1 sola dosis preprint. Jama 01.03.21 livingston Vacuna de J&J. Jama saadat 01.03.2021 Ac tras la primera dosis de vacuna. 03.03. Janssen Single Shot COVID 19 Vaccine Gets Emergency Use Authorization. MPR 01.03 Janssen's Single Shot COVID 19 Vaccine Gets Emergency Use Authorization. FDA 27.02.21 Issues Emergency Use Authorization for Third COVID-19 Vaccine. For Immediate Release: February 27, 2021 Today, the U.S.

FDA 27.02.21 Issues Emergency Use Authorization for Third COVID-19 Vaccine

Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older. “The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States,” said Acting FDA Commissioner Janet Woodcock, M.D. The FDA has determined that the Janssen COVID-19 Vaccine has met the statutory criteria for issuance of an EUA.

The Janssen COVID-19 Vaccine is manufactured using a specific type of virus called adenovirus type 26 (Ad26). FDA Evaluation of Available Safety Data FDA Evaluation of Available Effectiveness Data. 28.02.21 CDC Media Statement from CDC Director on Signing the Advisory Committee on Immunization Practices’ Recommendation to Use Janssen’s COVID-19 Vaccine in People 18 and Older. Today, I signed CDC’s Advisory Committee on Immunization Practices’ (ACIP) recommendation that endorsed the safety and effectiveness of Janssen (Johnson & Johnson)’s COVID-19 vaccine and its use in people age 18 and older.

28.02.21 CDC Media Statement from CDC Director on Signing the Advisory Committee on Immunization Practices’ Recommendation to Use Janssen’s COVID-19 Vaccine in People 18 and Older

This official CDC recommendation — which follows Saturday’s FDA decisionexternal icon to authorize emergency use of the vaccine — is another milestone toward an end to the pandemic. As vaccination scales up, so too does our nation’s overall protection from serious outcomes due to COVID-19. The Janssen vaccine has been shown to be safe and effective in preventing severe COVID-19 illness, hospitalization, and death. This vaccine is also another important tool in our toolbox to equitably vaccinate as many people as possible, as quickly as possible. As a one-dose vaccine, people do not have to return for a second dose to be protected. MPR 19.02.21 Pfizer BioNTech COVID 19 Vaccine Trial in Pregnant Women Begins; New Storage Data Submitted to FDA. MPR 25.02. Moderna Outlines Strategy to Address SARS CoV 2 Variants; Ships Variant Booster to NIH for Testing. JAMA creech 26.02.21 Vacunas rev. 25.02 MPR COVID 19 Vaccine Efficacy After First Dose Pfizer, Moderna, AstraZeneca. Pfizer 25.02. Nuevo estudio dosis booster vacuna eficacia variantes.

The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccineDiscussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or other new strains that may emerge as possible immune escape virus variants Based on in-vitro studies conducted to date and observations from real world evidence, the Companies have not observed changes to neutralizing antibody levels that would predict a significant reduction in protection provided by two doses of BNT162b2 NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc.

pfizer 25.02. Nuevo estudio dosis booster vacuna eficacia variantes

This press release features multimedia. View the full release here: Pfizer Disclosure Notice About BioNTech Pfizer: MPR 23.02.21 CDC Report Shows No Evidence of Unexpected Adverse Events With COVID 19 Vaccines. MPR 24.02.21 Pfizer BioNTech COVID 19 Vaccine Trial in Pregnant Women Begins; New Storage Data Submitted to FDA. FarmaAPCOVID19 20210225 Vacuna AstraZeneca. FarmaAP 20210225 Anafilaxia Adultos CS.

Nejm 24.02 Estudio RWD vacuna Pfizer. FDA 26.92 Eficacia vacuna J&J. Jama shimabukuro 21.02.21 Anafilaxia vacuna Covid. MSC ¿Puedo hacer vida normal después de la vacuna? MPR 19.02 Pfizer BioNTech COVID 19 Vaccine Trial in Pregnant Women Begins; New Storage Data Submitted to FDA. NYT 19.02.21 Studies Suggest People Who Had Covid-19 Should Get Single Vaccine Dose. Nearly 30 million people in the United States — and probably many others whose illnesses were never diagnosed — have been infected with the coronavirus so far.

NYT 19.02.21 Studies Suggest People Who Had Covid-19 Should Get Single Vaccine Dose

Should these people still be vaccinated? Two new studies answer that question with an emphatic yes. In fact, the research suggests that for these people just one dose of the vaccine is enough to turbocharge their antibodies and destroy the coronavirus — and even some more infectious variants. The results of these new studies are consistent with the findings of two others published over the past few weeks. Taken together, the research suggests that people who have had Covid-19 should be immunized — but a single dose of the vaccine may be enough. “I think it’s a really strong rationale for why people who were previously infected with Covid should be getting the vaccine,” said Jennifer Gommerman, an immunologist at the University of Toronto who was not involved in the new research.

The vaccines “even the playing field,” Dr. MMWR 19.02.21 First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021. Summary What is already known about this topic?

MMWR 19.02.21 First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021

Two COVID-19 vaccines have received Emergency Use Authorization for administration in the United States. In preauthorization clinical trials, local and systemic reactions were reported; no serious safety problems were detected. What is added by this report? Lancet 20.02 Vacuna Sputnik eficacia y seguridad. ACOG 04.02.21 Vaccinating Pregnant and Lactating Patients Against COVID-19. Last updated February 4, 2021 This Practice Advisory was developed by the American College of Obstetricians and Gynecologists’ Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group in collaboration with Laura E.

ACOG 04.02.21 Vaccinating Pregnant and Lactating Patients Against COVID-19

Riley, MD; Richard Beigi, MD; Denise J. Jamieson, MD, MPH; Brenna L. Hughes, MD, MSc; Geeta Swamy, MD; Linda O’Neal Eckert, MD; Mark Turrentine, MD; and Sarah Carroll, MPH. Summary of Key Information and Recommendations. Etrategia de vacunación MSC 3 act. 09.02.21. 18.02.21 JAMA Vacunas Covid. Nejm feb21 demora en la segunda dosis. MPR 17.02.21 Oxford AstraZeneca COVID 19 Vaccine New Study Results, Variant Coverage Update, Where Do We Stand. MPR 16.02. Eficacia vacuna J&J ENSEMBLE Trial J&J COVID 19 Vaccine Phase 3 Interim Analysis. MPR 12.02.21 Moderna Wants to Increase Number of Doses in COVID 19 Vaccine Vials. Jama shimabukuro 12.02.21 Anafilaxia mRNA vacunas. COVID-19 Vaccine Safety–Anaphylaxis and Allergic Reactions. [Skip to Content] [Skip to Content Landing] Claim CME Share Facebook Twitter LinkedIn Email Copy URL Infectious Diseases.

COVID-19 Vaccine Safety–Anaphylaxis and Allergic Reactions

MPR 10.02 Dr Fauci on COVID 19 Vaccines and Putting an End to the Pandemic. Jama 10.02.21 Expertos hablan sobre Covid vacunas, variantes... WHO 10.02.21 vacuna Astra Zeneca vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper (draft) Medscape 08.02.21 Anafilaxia y vacuna Covid. Medcape 05.02.21 Eficacia vacuna Sputnik. 05.02.21 AstraZeneca’s COVID 19 Vaccine Prevents Severe Disease, May Cut Transmission. MPR 05.02.21 Low Rates of Anaphylaxis Following Pfizer BioNTech COVID 19 Vaccination Clinical Advisor. NEJM Journal Watch 07.02.21 Vacuna Pfizer y linfadenopatía axilar. 04.02.21 Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate. NEW BRUNSWICK, N.J., Feb. 4, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S.

04.02.21 Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The Company's EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose vaccine met all primary and key secondary endpoints. The Company expects to have product available to ship immediately following authorization. "Today's submission for Emergency Use Authorization of our investigational single-shot COVID-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson.

SOURCE Johnson & Johnson. Lancet preprint Vacuna A-Z y cepa británica. 40 Pages Posted: 4 Feb 2021 Abstract Background: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19infection in the United Kingdom from November 2020 with a transmission advantage over the previous variants of the virus. Here we report efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19, against this variant in comparison with non-B.1.1.7 lineages. Methods: Volunteers enrolled in phase II/III vaccine efficacy studies in the United Kingdom and randomised 1:1 to receive ChAdOx1 nCoV-19 or a MenACWY control vaccine, providedupper airway swabs every week during the trial and also if they developed possible symptomatic COVID-19 infection. Swabs were tested by nucleic acid amplification test (NAAT) for SARS-CoV-2, and positive samples were sequenced through the COVID-19Genomics UK consortium (COG UK).

MPR 02.02.21 New COVID 19 Variants May Weaken Efficacy of Vaccines MPR. FACME – Federación de Asociaciones Científico Médicas Españolas – Covid-19: Documentos. MPR 05.02.21 Janssen Requests Emergency Use Authorization for Single Shot COVID 19 Vaccine. Jama livingston 03.02.2021 Dos dosis Vacunas Pfizer y Moderna. Jama meissner 05 02 2021 Seguridad Vacunas. MPR 03.02.21 Novavax’s Recombinant Nanoparticle COVID 19 Vaccine Shows Safety and Efficacy.

MPR 02.02.21 Johnson & Johnson’s COVID 19 Vaccine Phase 1 2a Trial Results. Jama livingston 03.02.2021 Necesidad de 2 dosis vacunas Moderna y Pfizer. MPR 03.02.21 AstraZeneca’s COVID 19 Vaccine Prevents Severe Disease, May Cut Transmission. 03.02.21 COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials. The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose. Results demonstrated vaccine efficacy of 76% (CI: 59% to 86%) after a first dose, with protection maintained to the second dose.

With an inter-dose interval of 12 weeks or more, vaccine efficacy increased to 82% (CI: 63%, 92%). The analysis also showed the potential for the vaccine to reduce asymptomatic transmission of the virus, based on weekly swabs obtained from volunteers in the UK trial. The data showed that PCR positive readings were reduced by 67% (CI: 49%, 78%) after a single dose, and 50% (CI: 38% to 59%) after the two dose regimen, supporting a substantial impact on transmission of the virus.

ContactsFor details on how to contact the Investor Relations Team, please click here. MPR 02.02.21 New COVID 19 Variants May Weaken Efficacy of Vaccines. 02.02.21 Lancet. Vacuna Sputnik. Emerging Infectious Diseases journal - CDC Post-Vaccination COVID-19 among Healthcare Workers, Israel - Vol27, N4—April 2021.

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Authors affiliation: Chaim Sheba Medical Center, Ramat-Gan, Israel. NYT 01.02.21 Have You Had Covid-19? Study Says You May Need Only One Vaccine Dose. Shannon Romano, a molecular biologist, came down with Covid late last March, about a week after she and her colleagues shut down their lab at Mount Sinai Hospital.

A debilitating headache came first, followed by a fever that kept rising, and then excruciating body aches. “I couldn’t sleep. I couldn’t move,” she said. “Every one of my joints just hurt inside.” It was not an experience she wanted to repeat — ever. 01.02.21 Ac postvacunación en personas que han tenido Covid vs naive. MPR 25.01.21 Moderna COVID 19 Vaccine Active Against Emerging Variants. NEJM Journal Watch 31.1.21 Are We Expecting Too Much from Our COVID 19 Vaccines. MPR 29.01.21 J&J Single Dose COVID 19 Vaccine 66% Effective at Preventing Moderate Severe Disease.

MPR 29.02.21 Novavax COVID 19 Vaccine Significantly Effective Against UK Variant. La EMA recomienda la autorización de la tercera vacuna frente a la COVID-19 - Agencia Española de Medicamentos y Productos Sanitarios. Fecha de publicación: 29 de enero de 2020 Categoría: la AEMPS, medicamentos de uso humano, vacunas, COVID-19 Referencia: AEMPS, 09/2021. Aprendamos de los errores con las vacunas para COVID-19. Encontramos en el Institute for Safe Medication Practices una interesante recopilación de errores que se han notificado desde mediados de diciembre hasta el 14 de enero en EEUU, derivados de la utilización de las vacunas para COVID19, tanto con la vacuna de Pfizer/BioNTech, como con la de Moderna, que traducimos y resumimos a continuación:

OSU enero 21 Vacuna Covid. JAMA Your COVID Vaccine Questions Answered. 25.01.21 WHO 2019 nCoV vaccines SAGE recommendation mRNA 1273 2021.1 eng. Medscape 25.01.21 Interrogantes sobre vacuna Covid. 25.01.21 Vacuna Moderna booster frente a nuevas cepas. Investors.modernatx. Out of an abundance of caution, launches clinical program to boost immunity to emerging variants Manuscript posted to preprint server; company to host conference call once manuscript is available --(BUSINESS WIRE)--Jan. 25, 2021-- . (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2. Enero 2021 preguntasrespuestas vacunascovid 19. Sano y salvo: Recomendaciones para utilizar con seguridad las vacunas frente a la COVID-19. Instituto para el Uso Seguro de los Medicamentos, Agencia Española de Medicamentos y Productos Sanitarios y Ministerio de Sanidad.

El Institute for Safe Medication Practices (ISMP) y otros organismos internacionales, a partir del análisis de los errores que han ocurrido con la utilización de las de la COVID-19 y de otras vacunas, han emitido recomendaciones para evitarlos dirigidas a las instituciones responsables de los programas de vacunación y a los profesionales que las implementan. El Instituto para el Uso Seguro de los Medicamentos, filial en España del ISMP, la Agencia Española de Medicamentos y Productos Sanitarios y el Ministerio de Sanidad han publicado un resumen de esas recomendaciones para utilizar con seguridad las vacunas frente a la COVID-19. MPR 21.01.21 Pfizer BioNTech COVID 19 Vaccine Elicits Response Against Key Mutation.

Bmj.19.01.21 ampliar intervalo entre vacunas. Object moved. Jama shimabukuro 21.01.21 Anafilaxia y vacuna Covid. NEJM Vaccine Covid Resource Center (incluye FAQ) 11.01. Video JAMA Coronavirus Vaccine Update With Arnold S. Monto, MD. Pfizer 08.01 vacuna actúa frente a nueva cepa. New York, NY and Mainz, Germany, January 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. The results were published on the preprint server bioRxiv and are available here. Rapidly spreading variants of SARS-CoV-2 have been reported, initially in the United Kingdom and South Africa.

These variants have multiple mutations in their spike or S glycoproteins, which are key targets of virus neutralizing antibodies. Though these two rapidly spreading viruses are different, they share the N501Y mutation, which is located in the receptor binding site of the spike protein and results in the virus’s spike protein binding more tightly to its receptor. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. Summary What is already known about this topic? Anaphylaxis is a severe, life-threatening allergic reaction that occurs rarely after vaccination. ACP Journals. 04.01.21 FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines. For Immediate Release: January 04, 2021 Statement From: Statement Author Leadership Role Commissioner of Food and Drugs - Food and Drug Administration.

(CDC) Clinical Considerations for Use of Pfizer-BioNTech COVID-19 Vaccine. Jama gostin 29.12 Deberían ser obligatorias las vacunas. FDA investigating allergic reactions to Pfizer vaccine reported in multiple states. COVID-19 Vaccines and Severe Allergic Reactions. Medscape Dec Comparación 3 vacunas. Vacunas Publicación Covid19 SFAP. JAMA COVID-19 Vaccines and Herd Immunity. CDC 14.12 Interim Clinical Considerations for Use of Pfizer-BioNTech COVID-19 Vaccine. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 in persons aged 16 years and older.

NYT 15.12 Moderna vs Pfizer. WASHINGTON — The coronavirus vaccine made by Moderna is highly protective, according to new data released on Tuesday, setting the stage for its emergency authorization this week by federal regulators and the start of its distribution across the country. The Food and Drug Administration intends to authorize emergency use of the vaccine on Friday, people familiar with the agency’s plans said. The decision would give millions of Americans access to a second coronavirus vaccine beginning as early as Monday. The Pfizer-BioNTech vaccine, cleared last week, was the first to be authorized. “This is great news, as this now brings us to two products with high levels of efficacy,” said Rupali Limaye, an associate scientist at Johns Hopkins Bloomberg School of Public Health.

JAMA Dec Coronavirus Vaccine FDA Update.